

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2	line25-28
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	line25-39
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	line55-66
Objectives	3	State specific objectives, including any prespecified hypotheses	4	line67-70
Methods				
Study design	4	Present key elements of study design early in the paper	4-5	line72,89,97,106
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-6	line72-117
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up		
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	4	line72-88
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		no matched studies
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4	line75-82
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6	line107-117
Bias	9	Describe any efforts to address potential sources of bias	4	line86-88
Study size	10	Explain how the study size was arrived at	4	line73-75

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6	line111-115
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6	line112-115
		(b) Describe any methods used to examine subgroups and interactions	6	line 111-115
		(c) Explain how missing data were addressed	IgG levels of 20 ITP patients were missing, we compared the data between the rest 41 ITP patients and 20 controls	
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed		
		Case-control study—If applicable, explain how matching of cases and controls was addressed	N/A	
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy		
		(e) Describe any sensitivity analyses	N/A	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	87 patients potentially eligible and examined for eligibility→61 patients were confirmed eligible and included in the study(exclusive of 13 patients with other autoimmune disease, 5 pregnant and 8 with acute infection)→all 61 patients completed follow-up and analyzed	
		(b) Give reasons for non-participation at each stage		
		(c) Consider use of a flow diagram		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	line82-88	
		(b) Indicate number of participants with missing data for each variable of interest	IgG levels of 20 ITP patients were missing. All the rest data of variables were complete.	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)		
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time		
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	6-10	line119,130,138,149,162,176,189
		Cross-sectional study—Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	α=0.05 , two sided	
		(b) Report category boundaries when continuous variables were categorized	N/A	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	
Discussion				
Key results	18	Summarise key results with reference to study objectives	16	line346-352
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16	line336-345
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16	line336-345
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-15	line245-319
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17	line354-355

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.